AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Cellular Therapy Gets More Precise: In Vivo CAR T, a New Treg Therapy, and Menin Inhibitor Maintenance
By Moataz Ellithi, MD
Cellular therapy for blood cancers is moving in two directions at once: toward manufacturing CAR T-cells directly inside a patient's body rather than in a lab
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Lymphoma and CLL at ASCO 2026: New Frontline and Relapsed-Setting Data
By Poornima Ramadas, MD
Lymphoma and CLL data at the 2026 ASCO Annual Meeting spanned the treatment continuum, from frontline diffuse large B-cell lymphoma (DLBCL) to relapsed/refractory disease across several lymphoma subtypes, to a striking early combination in frontline CLL.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
Managing Bispecific T-Cell Engager Toxicity: CRS and ICANs in Practice
By Allison Hamner, PharmD, BCPS
Bispecific T-cell engagers (BiTEs) offer major efficacy in hematologic malignancies, but their signature toxicities—cytokine release syndrome (CRS) and ICANS—require real-time vigilance and management similar to CAR T-cell therapy.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease
Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
By Adeel M. Khan, MD, MPH, MS
Multiple myeloma had another eventful year at the 2026 ASCO Annual Meeting, with notable data across nearly every stage of disease